<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Easton, J. Donald</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Apixaban Superior to Warfarin in Patients with Atrial Fibrillation as well as Prior Stroke or TIA</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">The recent Apixaban Compared with Warfarin in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack trial [Granger CB et al. N Engl J Med 2011; ARISTOTLE; NCT00412984] found apixaban to be superior to warfarin for stroke prevention in a wide range of atrial fibrillation (AF) patients, with significantly lower bleeding risk and lower risk of all-cause mortality [Littrell R, Flaker G. Expert Rev Cardiovasc Ther 2012]. This article results of a comparison of apixaban with warfarin in patients with AF and prior stroke or transient ischemic attack.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>